Market Based Terms Sample Clauses

Market Based Terms. The “Market Based Terms” shall mean market-based and commercially reasonable terms for the grant of a license to a therapeutic product in the Territories, including, but not limited to, upfront payments, royalties and milestone payments, taking into account all relevant factors, including comparable transactions, stage of development and market potential of the Compound, efficacy and safety of the Compound as evidenced in clinical studies conducted by the Company, potential labeling and product profile of the Compound, the potential competitiveness of alternative products to the Compound in the Territories, the patent position of the product, projected profitability (including projected pricing and reimbursement) and the likelihood of the Compound receiving regulatory approval.
View Source

Related to Market Based Terms

  • Amended Terms On and after the Amendment Effective Date, all references to the Credit Agreement in each of the Loan Documents shall hereafter mean the Credit Agreement as amended by this Amendment. Except as specifically amended hereby or otherwise agreed, the Credit Agreement is hereby ratified and confirmed and shall remain in full force and effect according to its terms.

  • Common Terms In the event of any conflict between the provisions of the Common Terms and the provisions of this Agreement, the provisions of this Agreement shall prevail, subject always to compliance with clause 10 (Non-Petition and Limited Recourse) of the Common Terms.

  • Extended Terms The Term of this Agreement may be extended by the Manager if the Resident applies in writing for an “Extension” in accordance with the Managers published policies about Term Extensions. Extensions are subject to availability. Priority will be given to Residents travelling from great distances, who demonstrate a special need, or who are enrolled in orientation or academic programs that begin early or continue beyond the Residence Term. Extensions may also be granted for any ‘Early Move-In’, ‘Late Move-Out’ or ‘Summer Residence’ programs offered by the Manager. Residents granted Extensions are subject to the fees detailed in Table 3. Any Resident found occupying a Room outside of the Term without approval from the Manager are subject to additional fees over and above those detailed in Table 3. Summer Semester 2020 N/A N/A $35.00/Day Academic Year 2020-2021 N/A N/A $35.00/Day Winter Semester 2021 N/A N/A $35.00/Day

  • INDEX OF DEFINED TERMS Capitalized terms in this Agreement shall have the defined meanings that appear in the provisions of the Agreement listed below. Acceptance Time 5.2(b) Acquisition Proposal 5.2(a) Adverse Recommendation Change 5.2(c) Affiliate 3.3(d) Agreement Preamble Alternative Acquisition Agreement 5.2(c) Assignee 9.5(a) award 3.3(b) Book-Entry Share 2.1(c) business day 9.10(b) CERCLA 3.18(b) Certificate of Merger 1.4 Certificate 2.1(c) Closing 1.5 Closing Amount Recitals Closing Date 1.5 Code 2.6 Company Preamble Company Balance Sheet 3.6(a) Company Board of Directors Recitals Company Disclosure Letter SECTION 3 Company Joint Venture 3.4(c) Company’s knowledge 9.10(b) Company Material Adverse Effect 3.1(a) Company Option 2.4(a) Company Preferred Stock 3.3(a) Company Quarterly Balance Sheet 3.7 Company Restricted Share 2.4(b) Company Restricted Stock 2.4(b) Company Rights 3.3(a) Company Rights Agreement 3.3(a) Company SEC Reports 3.5 Company Stockholder Approval 6.1 Company Stock Plans 2.4(a) Company Subsidiary 3.4(a) Confidentiality Agreement 1.2(c) Continuing Employee 6.11(b) CPR Recitals CPR Agreement Recitals Current D&O Insurance 6.8(b) Delisting Period 6.3 DGCL Recitals Dissenting Shares 2.3(a) DSU 2.4(c) Effective Time 1.4 Employee Release 6.11(d) Environmental Laws 3.18(e)(i) ERISA 3.16(a) ERISA Affiliate 3.16(b) Exchange Act 1.1(a) Exchange Fund 2.2(a) Expiration Date 1.1(a) FCPA 3.9(c) FDA 3.9(d) Good Clinical Practices 3.9(h) Good Laboratory Practices 3.9(h) Good Manufacturing Practices 3.9(i) Governmental Entity 9.10(b) Hazardous Materials 3.18(e)(ii) HSR Act 3.19 IC Plans 6.11(a) Incentive Compensation Plan 6.11(a) Indemnified Parties 6.8(a) Independent Directors 6.9(a) IRS 3.16(a) Laws 3.9(b) Layoff Laws 3.17(b) Maximum Premium 6.8(b) Merger 1.3(a) Merger Agreement Annex I Merger Consideration 2.1(c) Minimum Condition Annex I Notice Period 5.2(d) OECD Convention 3.9(c) Offer Recitals Offer Condition 1.1(a) Offer Documents 1.1(c) Offer Price Recitals Offer to Purchase 1.1(a) on a fully diluted basis 9.10(b) Outside Date 8.1(b)(ii) Parent Preamble Paying Agent 2.2(a) Performance-Based DSU 2.4(c) Permits 3.9 person 9.10(b) Plans 3.16(a) Post-Closing SEC Reports 6.3 Principal Stockholders Recitals Prior Plan 6.11(c) Program 3.9(k) Prohibited Payment 3.9(c) Proprietary Rights 3.12(a) Proxy Statement 1.8(a)(ii) Real Property 3.12(b) Regulation M-A 1.1(c) Release 3.18(e)(iii) Representatives 5.2(a) Reporting Tail Endorsement 6.8(b) Restraints 8.1(b)(i) Rights Agent Recitals Sales Incentive Compensation Plan 6.11(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act 3.6(b) Schedule 14D-9 1.2(b) Schedule TO 1.1(b) SEC 1.1(a) Securities Act 3.11(c) Severance 6.11(d) Shares Recitals Special Meeting 1.8(a)(i) Sub Preamble Sub Common Stock 2.1 Successor Plan 6.11(c) Superior Proposal 5.2(b) Surviving Corporation 1.3(a) Tax 3.15(a) Taxable 3.15(a) Tax Return 3.15(a) Tender Completion Time 6.2 Tender and Voting Agreements Recitals Terminated Employee 6.11(d) Termination Fee 8.2(b) Time-Vested DSU 2.4(c) Top-Up Option 1.10(a) Top-Up Shares 1.10(a) UK Bribery Act 3.9(c) THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) dated as of October 24, 2011 is among CUBIST PHARMACEUTICALS, INC. (“Parent”), a Delaware corporation, FRD ACQUISITION CORPORATION (“Sub”), a newly-formed Delaware corporation and a direct or indirect wholly-owned subsidiary of Parent, and ADOLOR CORPORATION (the “Company”), a Delaware corporation.

  • Defined Terms As used in this Agreement, the following terms have the meanings specified below: